Novavax vaccine shows 90% overall efficacy against Covid

Novavax Covid-19 vaccine has demonstrated 90 percent overall efficacy and 100 percent protection against moderate and severe Covid-19 disease in the Phase 3 trials. The company has said that Novavax has 93 percent efficacy against the predominantly circulating Variants of Concern and Variants of Interest of Covid-19 and has 91 percent efficacy in high-risk populations. Novavax also shows 100 percent efficacy against variants not considered Variants of Concern or Interest, said the company in its latest statement.